X
<

Johnson & Johnson's 1Q18 Earnings: What to Expect on April 17

PART:
1 2 3
Part 2
Johnson & Johnson's 1Q18 Earnings: What to Expect on April 17 PART 2 OF 3

Johnson & Johnson’s Revenue Estimates for 1Q18

Johnson & Johnson’s revenue estimates

As we discussed earlier, Johnson & Johnson (JNJ) is scheduled to report 9.2% growth in its revenues to $19.4 billion during 1Q18—compared to revenues of $17.8 billion in 1Q17.

Johnson &#038; Johnson’s Revenue Estimates for 1Q18

Interested in JNJ? Don't miss the next report.

Receive e-mail alerts for new research on JNJ

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

The above chart compares Johnson & Johnson’s actual revenues since 1Q17 and estimates for 1Q18.

Business segments in 1Q18

Johnson & Johnson’s business is divided into three business segments—the Pharmaceuticals segment, the Consumer segment, and the Medical Devices segment.

The Pharmaceuticals segment contributes over 45% of Johnson & Johnson’s total revenues. The segment is Johnson & Johnson’s largest revenue contributor. During 1Q18, the Pharmaceuticals segment is expected to report higher operating revenues. Foreign exchange is also expected to have a favorable impact on the revenues. The growth is expected to be driven by Tremfya, Simponi/Simponi Aria, and Stelara from the immunology franchise, Invega Sustenna from the the neuroscience franchise, Imbruvica, Zytiga, and Darzalex from oncology franchise, and Xarelto from the cardiovascular and metabolic franchise, and the inclusion of pulmonary hypertension products acquired from Actelion in 2017.

The Consumer segment is expected to report higher operating revenues. Foreign exchange is expected to have a positive impact on the revenues during 1Q18. The growth is expected to be driven by increased sales of beauty care products, women’s health products, over-the-counter products, and wound care products during 1Q18. Baby care products and oral care products are expected to report lower sales for 1Q18.

The Medical Devices segment is expected to report higher operating revenues. Foreign exchange is expected to have a positive impact on the revenues during 1Q18. The growth is expected to be driven by strong sales of general and advanced surgery products, knee and trauma products, the cardiovascular franchise, and contact lenses from the vision care franchise.

Notably, the iShares US Healthcare ETF (IYH) holds 10.6% of its total investments in Johnson & Johnson, 6.5% in Pfizer (PFE), 4.5% in AbbVie (ABBV), and 3.0% in Gilead Sciences (GILD).

Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!

X

Please select a profession that best describes you: